US Bancorp’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.3M Sell
29,781
-69
-0.2% -$32.2K 0.02% 365
2025
Q4
$13.5M Sell
29,850
-1,006
-3% -$434K 0.02% 378
2025
Q3
$12.1M Sell
30,856
-2,727
-8% -$1.14M 0.01% 399
2025
Q2
$15M Buy
33,583
+1,324
+4% +$610K 0.02% 369
2025
Q1
$15.6M Buy
32,259
+1,916
+6% +$893K 0.02% 359
2024
Q4
$12.2M Buy
30,343
+3,764
+14% +$1.74M 0.02% 400
2024
Q3
$12.4M Buy
26,579
+2,273
+9% +$1.09M 0.02% 393
2024
Q2
$11.4M Buy
24,306
+2,856
+13% +$1.24M 0.02% 399
2024
Q1
$8.97M Buy
21,450
+2,288
+12% +$967K 0.01% 450
2023
Q4
$7.8M Buy
19,162
+6,065
+46% +$2.24M 0.01% 476
2023
Q3
$4.55M Buy
13,097
+1,383
+12% +$484K 0.01% 562
2023
Q2
$4.12M Sell
11,714
-915
-7% -$308K 0.01% 588
2023
Q1
$3.98M Buy
12,629
+183
+1% +$54.9K 0.01% 600
2022
Q4
$3.59M Sell
12,446
-726
-6% -$221K 0.01% 627
2022
Q3
$3.81M Buy
13,172
+578
+5% +$166K 0.01% 575
2022
Q2
$3.55M Sell
12,594
-3,107
-20% -$832K 0.01% 622
2022
Q1
$4.1M Buy
15,701
+1,512
+11% +$359K 0.01% 619
2021
Q4
$3.12M Buy
14,189
+1,895
+15% +$368K ﹤0.01% 749
2021
Q3
$2.23M Sell
12,294
-474
-4% -$92.5K ﹤0.01% 836
2021
Q2
$2.58M Sell
12,768
-3,408
-21% -$713K ﹤0.01% 791
2021
Q1
$3.48M Buy
16,176
+2,068
+15% +$454K 0.01% 651
2020
Q4
$3.33M Buy
14,108
+922
+7% +$212K 0.01% 635
2020
Q3
$3.59M Buy
13,186
+972
+8% +$268K 0.01% 570
2020
Q2
$3.55M Sell
12,214
-328
-3% -$88.9K 0.01% 564
2020
Q1
$2.98M Buy
12,542
+2,052
+20% +$471K 0.01% 564
2019
Q4
$2.3M Buy
10,490
+477
+5% +$96.5K 0.01% 723
2019
Q3
$1.7M Buy
10,013
+707
+8% +$125K ﹤0.01% 813
2019
Q2
$1.71M Buy
9,306
+319
+4% +$55.8K ﹤0.01% 854
2019
Q1
$1.65M Buy
8,987
+685
+8% +$127K ﹤0.01% 847
2018
Q4
$1.38M Buy
8,302
+1,051
+14% +$182K ﹤0.01% 869
2018
Q3
$1.4M Sell
7,251
-118
-2% -$21K ﹤0.01% 946
2018
Q2
$1.25M Sell
7,369
-1,315
-15% -$204K ﹤0.01% 997
2018
Q1
$1.42M Buy
8,684
+1,669
+24% +$273K ﹤0.01% 935
2017
Q4
$1.05M Sell
7,015
-182
-3% -$26.9K ﹤0.01% 1076
2017
Q3
$1.09M Buy
7,197
+456
+7% +$68.6K ﹤0.01% 1038
2017
Q2
$869K Sell
6,741
-583
-8% -$70.2K ﹤0.01% 1124
2017
Q1
$801K Buy
7,324
+3,749
+105% +$330K ﹤0.01% 1187
2016
Q4
$263K Sell
3,575
-13,961
-80% -$1.14M ﹤0.01% 1678
2016
Q3
$1.53M Buy
17,536
+3,785
+28% +$358K 0.01% 836
2016
Q2
$1.18M Buy
13,751
+10,530
+327% +$910K ﹤0.01% 927
2016
Q1
$256K Sell
3,221
-1,381
-30% -$125K ﹤0.01% 1587
2015
Q4
$579K Sell
4,602
-715
-13% -$86.3K ﹤0.01% 1237
2015
Q3
$554K Buy
5,317
+1,026
+24% +$132K ﹤0.01% 1251
2015
Q2
$530K Buy
4,291
+728
+20% +$91.7K ﹤0.01% 1333
2015
Q1
$420K Buy
3,563
+772
+28% +$92.5K ﹤0.01% 1433
2014
Q4
$331K Buy
2,791
+1,114
+66% +$125K ﹤0.01% 1550
2014
Q3
$189K Sell
1,677
-110
-6% -$10.5K ﹤0.01% 1795
2014
Q2
$170K Buy
1,787
+1,352
+311% +$94.8K ﹤0.01% 1876
2014
Q1
$31K Sell
435
-1,207
-74% -$95.6K ﹤0.01% 2671
2013
Q4
$122K Sell
1,642
-3,907
-70% -$272K ﹤0.01% 1993
2013
Q3
$421K Buy
5,549
+4,886
+737% +$389K ﹤0.01% 1336
2013
Q2
$53K Buy
+663
New +$48.8K ﹤0.01% 2298

Other funds holding VRTX

US Bancorp's VRTX Position: Q1 2026 in Review

US Bancorp reduced its Vertex Pharmaceuticals (VRTX) stake by 0.23% in Q1 2026, selling an estimated $32.2K and leaving 29,781 shares worth $13.3M. The position accounts for 0.02% of the portfolio, ranked #365.

US Bancorp first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $15.6M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • US Bancorp held 29,781 shares of Vertex Pharmaceuticals worth $13.3M as of Q1 2026.
  • US Bancorp sold 69 Vertex Pharmaceuticals shares in Q1 2026, an estimated $32.2K.
  • Vertex Pharmaceuticals made up 0.02% of US Bancorp's portfolio in Q1 2026, its #365 holding.
  • US Bancorp first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • US Bancorp's Vertex Pharmaceuticals position peaked at $15.6M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.